시장보고서
상품코드
1526338

세계의 생체흡수성 스텐트 시장

Bioresorbable Stents

발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 125 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

생체흡수성 스텐트 세계 시장은 2030년까지 12억 달러에 이를 전망

2023년에 5억 5,440만 달러로 추정되는 생체흡수성 스텐트 세계 시장은 2030년에는 12억 달러에 이르고, 분석 기간인 2023-2030년간 CAGR은 12.1%를 나타낼 전망입니다. 폴리머 기반 생체흡수성 스텐트는 본 보고서에서 분석한 부문 중 하나이며, CAGR 12.8%를 나타내고, 분석 기간 종료시에는 9억 520만 달러에 이를 것으로 예측됩니다. 금속 기반 생체흡수성 스텐트 분야의 성장률은 분석 기간중 CAGR 10.2%로 추정됩니다.

세계 생체흡수성 스텐트 시장 동향 및 촉진요인 정리

생체흡수성 혈관 비계(BVS)라고도 불리는 생체흡수성 스텐트는 중재적 심장병학에서 중요한 진보를 상징합니다. 이 스텐트는 시술 후 동맥을 일시적으로 지지하고 시간이 지남에 따라 서서히 용해되어 자연 혈관을 남길 수 있도록 설계되었습니다. 체내에 영구적으로 남아있는 기존의 금속 스텐트와는 달리, 생체흡수성 스텐트는 폴리유산(PLA)과 같이 자연적으로 분해되어 체내에 흡수되는 물질로 구성되어 있습니다. 이러한 일시적인 특성으로 인해 만성 염증 및 후기 혈전증과 같은 영구적 임플란트에 수반되는 장기적인 위험을 줄일 수 있습니다. 임상시험에서 생체흡수성 스텐트는 관상동맥 질환 치료에 효과적임이 입증되었으며, 금속 스텐트에 필적하는 결과를 보여주며, 시간이 지남에 따라 혈관의 본래 기능과 유연성을 회복하는 장점이 있습니다.

생체흡수성 스텐트의 개발은 광범위한 조사와 기술 혁신을 통해 추진되어 왔습니다. 이 스텐트는 혈관 성형술 후 중요한 치유 기간 동안 동맥에 필요한 기계적 지지력을 제공하도록 설계되었습니다. 시간이 지남에 따라 스텐트는 점차 성능이 저하되어 장기적인 합병증의 위험을 줄입니다. 또한, 생체흡수성 스텐트는 종종 항증식제로 코팅되어 재협착, 즉 동맥의 재협착을 더욱 예방합니다. 기계적 지지와 약물 전달의 이중 기능은 환자의 치료 결과를 향상시킵니다. 또한 첨단 영상 처리 기술과 정밀 공학의 사용은 이러한 스텐트의 배치와 효과를 개선하여 더 많은 환자와 임상 상황에서 실행 가능한 선택이 될 수 있도록 개선되었습니다.

생체흡수성 스텐트 시장의 성장은 몇 가지 요인에 의해 주도되고 있습니다. 첫째, 전 세계적으로 심혈관 질환, 특히 관상동맥 질환의 유병률이 증가함에 따라 효과적이고 혁신적인 치료 옵션이 필요합니다. 둘째, 환자와 의료진 사이에서 최소 침습적 시술에 대한 수요가 증가하면서 생체흡수성 스텐트의 채택이 가속화되고 있습니다. 이러한 스텐트는 기존 방식에 대한 유망한 대안을 제공하며, 보다 최소 침습적인 개입을 추구하는 추세에 부합합니다. 셋째, 생체 재료와 스텐트 설계의 기술적 진보로 인해 생체흡수성 스텐트의 성능과 안전성이 향상되어 임상의에게 더욱 매력적으로 다가오고 있습니다. 마지막으로, 이러한 스텐트에 대한 환자들의 인식과 수용도가 높아진 데다 일부 지역의 유리한 상환 정책과 결합하여 시장 성장을 더욱 촉진하고 있습니다. 이러한 요인들이 복합적으로 작용하여 현대 심혈관 치료 패러다임에서 생체흡수성 스텐트의 역할이 확대되고 있음을 뒷받침하고 있습니다.

조사 대상 기업 예(주요 25개사)

  • Abbott Laboratories, Inc.
  • Boston Scientific Corporation
  • Biotronik SE & Co. KG
  • Eurocor GmbH
  • Biosensors International Group Ltd.
  • Elixir Medical Corporation
  • InSitu Technologies, Inc.
  • Kyoto Medical Planning Co., Ltd.
  • Medinol Ltd.
  • Lepu Medical Technology(Beijing) Co., Ltd.
  • Alvimedica Saglik Ekipmanlari Pazarlama Satis ve Dagitim A.S.
  • Meril Life Sciences Pvt., Ltd.
  • Arterial Remodeling Technologies SA
  • iVascular S.L.U
  • Endocor GmbH

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 세계 시장 개요
  • 시장 전망
  • 경쟁
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 유럽
  • 아시아태평양
  • 세계 기타 지역

제4장 경쟁

LSH 24.08.09

Global Bioresorbable Stents Market to Reach US$1.2 Billion by 2030

The global market for Bioresorbable Stents estimated at US$554.4 Million in the year 2023, is expected to reach US$1.2 Billion by 2030, growing at a CAGR of 12.1% over the analysis period 2023-2030. Polymer-based Bioresorbable Stents, one of the segments analyzed in the report, is expected to record a 12.8% CAGR and reach US$905.2 Million by the end of the analysis period. Growth in the Metal-based Bioresorbable Stents segment is estimated at 10.2% CAGR over the analysis period.

Global Bioresorbable Stents Market - Key Trends & Drivers Summarized

Bioresorbable stents, also known as bioresorbable vascular scaffolds (BVS), represent a significant advancement in interventional cardiology. These stents are designed to provide temporary support to the artery after a procedure, gradually dissolving over time and leaving behind a natural vessel. Unlike traditional metal stents, which remain permanently in the body, bioresorbable stents are composed of materials like polylactic acid (PLA) that naturally break down and are absorbed by the body. This temporary nature reduces the long-term risks associated with permanent implants, such as chronic inflammation and late-stage thrombosis. Clinical trials have demonstrated the efficacy of bioresorbable stents in treating coronary artery disease, showing comparable outcomes to metallic stents with the added benefit of restoring the vessel's natural function and flexibility over time.

The development of bioresorbable stents has been propelled by extensive research and technological innovations. These stents are engineered to provide the necessary mechanical support to the artery during the critical healing period post-angioplasty. Over time, the stent gradually degrades, reducing the risk of long-term complications. Additionally, bioresorbable stents are often coated with antiproliferative drugs to further prevent restenosis, or re-narrowing of the artery. This dual function of providing mechanical support and drug delivery enhances the therapeutic outcomes for patients. Furthermore, the use of advanced imaging techniques and precision engineering has improved the deployment and efficacy of these stents, making them a viable option for a broader range of patients and clinical scenarios.

The growth in the bioresorbable stents market is driven by several factors. Firstly, there is an increasing prevalence of cardiovascular diseases globally, particularly coronary artery disease, which necessitates effective and innovative treatment options. Secondly, the rising demand for minimally invasive procedures among patients and healthcare providers is fueling the adoption of bioresorbable stents. These stents offer a promising alternative to traditional methods, aligning with the trend towards less invasive interventions. Thirdly, technological advancements in biomaterials and stent design are enhancing the performance and safety profile of bioresorbable stents, making them more attractive to clinicians. Lastly, the growing awareness and acceptance of these stents among patients, coupled with favorable reimbursement policies in several regions, are further boosting market growth. The confluence of these factors underscores the expanding role of bioresorbable stents in modern cardiovascular treatment paradigms.

Select Competitors (Total 25 Featured) -

  • Abbott Laboratories, Inc.
  • Boston Scientific Corporation
  • Biotronik SE & Co. KG
  • Eurocor GmbH
  • Biosensors International Group Ltd.
  • Elixir Medical Corporation
  • InSitu Technologies, Inc.
  • Kyoto Medical Planning Co., Ltd.
  • Medinol Ltd.
  • Lepu Medical Technology (Beijing) Co., Ltd.
  • Alvimedica Saglik Ekipmanlari Pazarlama Satis ve Dagitim A.S.
  • Meril Life Sciences Pvt., Ltd.
  • Arterial Remodeling Technologies SA
  • iVascular S.L.U
  • Endocor GmbH

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Bioresorbable Stents - Global Key Competitors Percentage Market Share in 2024 (E)
    • Coronary Artery Disease (CAD) - A Perspective
    • Causes and Symptoms
    • Treatment Options for Coronary Artery Disease
    • Percutaneous Coronary Intervention (PCI)
    • Coronary Stenting
    • Types of Coronary Stents
    • Bare Metal Stents (BMS)
    • Drug Eluting Stents (DES)
    • Bioresorbable Scaffolds
    • Design and Composition of Bioresorbable Scaffolds
    • Different Types of Bioresorbable Scaffolds
    • Metallic Bioresorbable Scaffolds
    • Polymer Bioresorbable Scaffolds
    • Degradation Period of Select Bioabsorbable Materials
    • Challenges
    • Clinical Characteristics of Various Coronary Stents
    • Other Treatment Options for Coronary Heart Disease
    • Coronary Artery Bypass Grafting (CABG)
    • Minimally Invasive Direct Coronary Artery Bypass (MIDCAB)
    • TransMyocardial Laser Revascularization (TMR)
    • Peripheral Arterial Disease: Understanding the Stealthy Peril
    • Treatment for PAD
    • Stenting- A Treatment Option for PAD
    • BioResorbable Stents - A Prelude
    • Bioresorbable Vascular Scaffolds: Advantages and Challenges
    • Bioresorbable Stents - A Revolutionary Technology, Riddled with Controversies
    • Abbott Stops Sales of the Once Promising 'Absorb' Bioresorbable Stents due to Adverse Events
    • Impact of Abbott's Withdrawal of Absorb on the Bioresorbable Stent Industry
  • GLOBAL MARKET OVERVIEW
    • Global Bioresorbable Stents Set to Witness Growth in Future
    • Europe Dominates, Asia-Pacific Exhibits Fastest Growth
    • CAD Constitutes the Leading Application
    • Metallic Vs. Polymer-based Stents
    • Bioabsorbable Metallic Stents
    • Bioabsorbable Polymer Stents
    • Disappointing Results by Absorb to Increase Focus on Metallic Stents
    • Availability of Alternative Treatments - Hindrance to Market Growth
    • Market Challenges
  • MARKET OUTLOOK
    • Bioresorbable and Integrated Biosensor Technology to Redefine Future of Vascular Stents
    • The Future of BRS Technology
  • COMPETITION
    • Select Approved Bioresorbable Scaffolds
    • Select Bioresorbable Stents in Pipeline
    • Abbott Revives Bioresorbable Stent Clinical Trials to Evaluate New Esprit Scaffold
    • Recent Market Activity
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Polymeric Resorbable Scaffolds Hold a Major Market Share
    • The Absorb BRS program
    • Desaminotyrosine Polycarbonate-based BRS
    • The FANTOM program
    • Magnesium-based BRS
    • The Magmaris program
    • Iron-based BRS
    • Global Menace of Coronary Artery Disease (CAD) - A Major Growth Driver
    • Global Annual Medical Cost of CVD in the United States: 2015-2030
    • Fatalities by Heart Conditions - Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
    • Ageing Demographics and Longer Life Expectancy Bolsters Market Growth
    • Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
    • Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
    • Rising Middle Class Population Aids Growth
    • Global Middle Class Population (in Millions) by Geographic Region: 2010, 2020P & 2030P
    • Rising Healthcare Expenditure: Opportunities in Store
    • World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
    • Healthcare Costs as a % of GDP by Country for the Years 2020 & 2023
    • Risk of CAD in Obesity Offers Prospects for Coronary Stenting
    • Obesity Prevalence Rate (%) in Select Countries for the Years 2019 and 2030P
    • Diabetics at Higher Risk of Heart Diseases
    • TABLE 15: Diabetes Prevalence Worldwide by Region: Number of Adults (20-79 Years) with Diabetes in 2015 and 2040
    • The Hypertension-Cholesterol Link to Drive Demand
    • Hypertension Prevalence (%) Worldwide by Region in Male and Females Aged 25+ Years
    • Metal Bioresorbable scaffolds Exhibit Improved Performance Compared to Polymer Stents
    • Metal Stents Vis-a-Vis Other Stents
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Bioresorbable Stents by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 2: World 7-Year Perspective for Bioresorbable Stents by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
    • TABLE 3: World Recent Past, Current & Future Analysis for Polymer-based by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 4: World 7-Year Perspective for Polymer-based by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Metal-based by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World 7-Year Perspective for Metal-based by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Coronary Artery Disease/CAD by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 8: World 7-Year Perspective for Coronary Artery Disease/CAD by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 9: World Recent Past, Current & Future Analysis for Peripheral Artery Disease/PAD by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 10: World 7-Year Perspective for Peripheral Artery Disease/PAD by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World 7-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Cardiovascular Centers by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 14: World 7-Year Perspective for Cardiovascular Centers by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 15: World Bioresorbable Stents Market Analysis of Annual Sales in US$ Thousand for Years 2020 through 2030

III. MARKET ANALYSIS

  • EUROPE
    • Bioresorbable Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 16: Europe Recent Past, Current & Future Analysis for Bioresorbable Stents by Material - Polymer-based and Metal-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 17: Europe 7-Year Perspective for Bioresorbable Stents by Material - Percentage Breakdown of Value Sales for Polymer-based and Metal-based for the Years 2024 & 2030
    • TABLE 18: Europe Recent Past, Current & Future Analysis for Bioresorbable Stents by Application - Coronary Artery Disease/CAD and Peripheral Artery Disease/PAD - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 19: Europe 7-Year Perspective for Bioresorbable Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease/CAD and Peripheral Artery Disease/PAD for the Years 2024 & 2030
    • TABLE 20: Europe Recent Past, Current & Future Analysis for Bioresorbable Stents by End-Use - Hospitals and Cardiovascular Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Europe 7-Year Perspective for Bioresorbable Stents by End-Use - Percentage Breakdown of Value Sales for Hospitals and Cardiovascular Centers for the Years 2024 & 2030
  • ASIA-PACIFIC
    • Bioresorbable Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 22: Asia-Pacific Recent Past, Current & Future Analysis for Bioresorbable Stents by Material - Polymer-based and Metal-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 23: Asia-Pacific 7-Year Perspective for Bioresorbable Stents by Material - Percentage Breakdown of Value Sales for Polymer-based and Metal-based for the Years 2024 & 2030
    • TABLE 24: Asia-Pacific Recent Past, Current & Future Analysis for Bioresorbable Stents by Application - Coronary Artery Disease/CAD and Peripheral Artery Disease/PAD - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 25: Asia-Pacific 7-Year Perspective for Bioresorbable Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease/CAD and Peripheral Artery Disease/PAD for the Years 2024 & 2030
    • TABLE 26: Asia-Pacific Recent Past, Current & Future Analysis for Bioresorbable Stents by End-Use - Hospitals and Cardiovascular Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Asia-Pacific 7-Year Perspective for Bioresorbable Stents by End-Use - Percentage Breakdown of Value Sales for Hospitals and Cardiovascular Centers for the Years 2024 & 2030
  • REST OF WORLD
    • TABLE 28: Rest of World Recent Past, Current & Future Analysis for Bioresorbable Stents by Material - Polymer-based and Metal-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 29: Rest of World 7-Year Perspective for Bioresorbable Stents by Material - Percentage Breakdown of Value Sales for Polymer-based and Metal-based for the Years 2024 & 2030
    • TABLE 30: Rest of World Recent Past, Current & Future Analysis for Bioresorbable Stents by Application - Coronary Artery Disease/CAD and Peripheral Artery Disease/PAD - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 31: Rest of World 7-Year Perspective for Bioresorbable Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease/CAD and Peripheral Artery Disease/PAD for the Years 2024 & 2030
    • TABLE 32: Rest of World Recent Past, Current & Future Analysis for Bioresorbable Stents by End-Use - Hospitals and Cardiovascular Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Rest of World 7-Year Perspective for Bioresorbable Stents by End-Use - Percentage Breakdown of Value Sales for Hospitals and Cardiovascular Centers for the Years 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제